Immunotherapy targets in pediatric cancer

Rimas J. Orentas, Daniel W. Lee, Crystal Mackall

Research output: Contribution to journalArticle

Abstract

Immunotherapy for cancer has shown increasing success and there is ample evidence to expect that progress gleaned in immune targeting of adult cancers can be translated to pediatric oncology. This manuscript reviews principles that guide selection of targets for immunotherapy of cancer, emphasizing the similarities and distinctions between oncogene-inhibition targets and immune targets. It follows with a detailed review of molecules expressed by pediatric tumors that are already under study as immune targets or are good candidates for future studies of immune targeting. Distinctions are made between cell surface antigens that can be targeted in an MHC independent manner using antibodies, antibody derivatives, or chimeric antigen receptors versus intracellular antigens which must be targeted with MHC restricted T cell therapies. Among the most advanced immune targets for childhood cancer are CD19 and CD22 on hematologic malignancies, GD2 on solid tumors, and NY-ESO-1 expressed by a majority of synovial sarcomas, but several other molecules reviewed here also have properties which suggest that they too could serve as effective targets for immunotherapy of childhood cancer.

Original languageEnglish (US)
Article number00003
JournalFrontiers in Oncology
Volume2
Issue numberJAN
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Immunotherapy
Pediatrics
Neoplasms
Synovial Sarcoma
Antigen Receptors
Antibodies
Hematologic Neoplasms
Surface Antigens
Cell- and Tissue-Based Therapy
Oncogenes
T-Lymphocytes
Antigens

Keywords

  • Adoptive immunotherapy
  • Antibody therapy
  • Chimeric antigen receptor
  • Immunotherapy
  • Pediatric cancer
  • Tumor antigens
  • Tumor immunity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Orentas, R. J., Lee, D. W., & Mackall, C. (2012). Immunotherapy targets in pediatric cancer. Frontiers in Oncology, 2(JAN), [00003]. https://doi.org/10.3389/fonc.2012.00003

Immunotherapy targets in pediatric cancer. / Orentas, Rimas J.; Lee, Daniel W.; Mackall, Crystal.

In: Frontiers in Oncology, Vol. 2, No. JAN, 00003, 2012.

Research output: Contribution to journalArticle

Orentas, RJ, Lee, DW & Mackall, C 2012, 'Immunotherapy targets in pediatric cancer', Frontiers in Oncology, vol. 2, no. JAN, 00003. https://doi.org/10.3389/fonc.2012.00003
Orentas, Rimas J. ; Lee, Daniel W. ; Mackall, Crystal. / Immunotherapy targets in pediatric cancer. In: Frontiers in Oncology. 2012 ; Vol. 2, No. JAN.
@article{6896409e367f4c1aaa014123d7826d96,
title = "Immunotherapy targets in pediatric cancer",
abstract = "Immunotherapy for cancer has shown increasing success and there is ample evidence to expect that progress gleaned in immune targeting of adult cancers can be translated to pediatric oncology. This manuscript reviews principles that guide selection of targets for immunotherapy of cancer, emphasizing the similarities and distinctions between oncogene-inhibition targets and immune targets. It follows with a detailed review of molecules expressed by pediatric tumors that are already under study as immune targets or are good candidates for future studies of immune targeting. Distinctions are made between cell surface antigens that can be targeted in an MHC independent manner using antibodies, antibody derivatives, or chimeric antigen receptors versus intracellular antigens which must be targeted with MHC restricted T cell therapies. Among the most advanced immune targets for childhood cancer are CD19 and CD22 on hematologic malignancies, GD2 on solid tumors, and NY-ESO-1 expressed by a majority of synovial sarcomas, but several other molecules reviewed here also have properties which suggest that they too could serve as effective targets for immunotherapy of childhood cancer.",
keywords = "Adoptive immunotherapy, Antibody therapy, Chimeric antigen receptor, Immunotherapy, Pediatric cancer, Tumor antigens, Tumor immunity",
author = "Orentas, {Rimas J.} and Lee, {Daniel W.} and Crystal Mackall",
year = "2012",
doi = "10.3389/fonc.2012.00003",
language = "English (US)",
volume = "2",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "JAN",

}

TY - JOUR

T1 - Immunotherapy targets in pediatric cancer

AU - Orentas, Rimas J.

AU - Lee, Daniel W.

AU - Mackall, Crystal

PY - 2012

Y1 - 2012

N2 - Immunotherapy for cancer has shown increasing success and there is ample evidence to expect that progress gleaned in immune targeting of adult cancers can be translated to pediatric oncology. This manuscript reviews principles that guide selection of targets for immunotherapy of cancer, emphasizing the similarities and distinctions between oncogene-inhibition targets and immune targets. It follows with a detailed review of molecules expressed by pediatric tumors that are already under study as immune targets or are good candidates for future studies of immune targeting. Distinctions are made between cell surface antigens that can be targeted in an MHC independent manner using antibodies, antibody derivatives, or chimeric antigen receptors versus intracellular antigens which must be targeted with MHC restricted T cell therapies. Among the most advanced immune targets for childhood cancer are CD19 and CD22 on hematologic malignancies, GD2 on solid tumors, and NY-ESO-1 expressed by a majority of synovial sarcomas, but several other molecules reviewed here also have properties which suggest that they too could serve as effective targets for immunotherapy of childhood cancer.

AB - Immunotherapy for cancer has shown increasing success and there is ample evidence to expect that progress gleaned in immune targeting of adult cancers can be translated to pediatric oncology. This manuscript reviews principles that guide selection of targets for immunotherapy of cancer, emphasizing the similarities and distinctions between oncogene-inhibition targets and immune targets. It follows with a detailed review of molecules expressed by pediatric tumors that are already under study as immune targets or are good candidates for future studies of immune targeting. Distinctions are made between cell surface antigens that can be targeted in an MHC independent manner using antibodies, antibody derivatives, or chimeric antigen receptors versus intracellular antigens which must be targeted with MHC restricted T cell therapies. Among the most advanced immune targets for childhood cancer are CD19 and CD22 on hematologic malignancies, GD2 on solid tumors, and NY-ESO-1 expressed by a majority of synovial sarcomas, but several other molecules reviewed here also have properties which suggest that they too could serve as effective targets for immunotherapy of childhood cancer.

KW - Adoptive immunotherapy

KW - Antibody therapy

KW - Chimeric antigen receptor

KW - Immunotherapy

KW - Pediatric cancer

KW - Tumor antigens

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=84861125284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861125284&partnerID=8YFLogxK

U2 - 10.3389/fonc.2012.00003

DO - 10.3389/fonc.2012.00003

M3 - Article

C2 - 22645714

AN - SCOPUS:84861125284

VL - 2

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - JAN

M1 - 00003

ER -